Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.
Displaying 1347 questions Show Answers
To ask the Scottish Government what its position is on the National Entitlement Card not being accepted on the Glasgow Subway service, and what discussions it has had or plans with Glasgow City Council regarding this.
To ask the Scottish Government, in light of the recent subsidy given to charities in recognition of their palliative care for children, what criteria other charities providing palliative care for children would need to meet in order to be eligible to receive a similar subsidy.
To ask the Scottish Government what action it is taking to reduce waiting lists for operations in NHS Grampian for (a) cancer and (b) other patients, and whether this will include providing funding for (i) hiring specialist nurses and (ii) procedures to be carried out in the private sector.
To ask the Scottish Government when the administration for personal independence payments will be fully implemented.
To ask the Scottish Government what action it is taking to reduce the risk of human error arising from the digitised scanning of exam papers.
To ask the Scottish Government for what reason Student Awards Agency For Scotland (SAAS) loans are based on parental income and what criteria SAAS used to set the current bands.
To ask the Scottish Government what its response is to reports that digitised "one-size-fits-all" exams are being introduced in many higher education humanities subjects.
To ask the Scottish Government what action it is taking to support people who experience withdrawal symptoms caused by so-called over-the-counter drugs.
To ask the Scottish Government what action it takes to ensure that children with autism who display violent behaviour have access to locally-based support.
To ask the Scottish Government what analysis it has carried out of the use of the drug, Ibrutinib, as a second-line therapy treatment for chronic lymphocytic leukaemia.